目的 探討蘇合香丸聯(lián)合阿加曲班治療急性腦梗死患者的臨床療效。方法 選擇2019年12月—2021年9月河南省直屬機(jī)關(guān)第一門診部收治的82例急性腦梗死患者，隨機(jī)分為對(duì)照組和治療組，每組各41例。對(duì)照組靜脈滴注阿加曲班注射液，10 mg/次，2次/d。治療組在對(duì)照組的基礎(chǔ)上口服蘇合香丸，1丸/次，2次/d。兩組患者連續(xù)治療10 d。觀察兩組患者臨床療效，比較治療前后兩組患者癥狀好轉(zhuǎn)時(shí)間，血清因子白細(xì)胞介素-6（IL-6）、同型半胱氨酸（Hcy）、腫瘤壞死因子-α（TNF-α）、超敏C反應(yīng)蛋白（CRP）水平及神經(jīng)功缺損程度（NIHSS）評(píng)分和不良反應(yīng)發(fā)生率。結(jié)果 治療后，治療組臨床有效率明顯高于對(duì)照組（97.56%vs 78.05%，P<0.05）。治療后，治療組臨床出現(xiàn)的肢體感覺減退、自理能力下降、中樞性面癱、感覺性失語等癥狀好轉(zhuǎn)時(shí)間均早于對(duì)照組（P<0.05）。治療后，兩組患者血清因子IL-6、Hcy、TNF-α和CRP水平，及NIHSS評(píng)分均明顯下降（P<0.05），且治療組明顯低于對(duì)照組（P<0.05）。治療組不良反應(yīng)發(fā)生率為7.32%，明顯低于對(duì)照組的17.07%（P<0.05）。結(jié)論 蘇合香丸聯(lián)合阿加曲班治療急性腦梗死，能有效改善急性腦梗死癥狀，對(duì)腦神經(jīng)損傷程度好轉(zhuǎn)明顯，并有效降低炎癥反應(yīng)。

Objective To explore the clinical effect of Suhexiang Pills combined with argatroban in treatment of acute ischemic stroke. Methods Patients (82 cases) with acute ischemic stroke in the First Outpatient Department of Organs Directly under Henan Province from December 2019 to September 2021 were randomly divided into control and treatment group, and each group had 41 cases. Patients in the control group were iv administered with Argatroban Injection, 10 mg/time, twice daily. Patients in the treatment group were po administered with Suhexiang Pills on the basis of the control group, 1 pill/time, twice daily. Patients in two groups were treated for 10 d. After treatment, the clinical evaluation was evaluated, the improvement time of symptoms, serum factors levels IL-6, Hcy, TNF-α and CRP, NIHSS scores, incidence of adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was significantly higher than that of the control group (97.56% vs 78.05%, P < 0.05). After treatment, the improvement time of clinical symptoms such as decreased limb sensation, decreased self-care ability, central facial paralysis and sensory aphasia in the treatment group was earlier than that in the control group (P < 0.05). After treatment, the levels of serum factors IL-6, Hcy, TNF-α and CRP and NIHSS scores in two groups were significantly decreased (P < 0.05), and which in the treatment group were significantly lower than those in the control group (P < 0.05). The incidence of adverse reactions in the treatment group was 7.32%, and which was lower than 17.07% in the control group (P < 0.05). Conclusion The combined treatment of Suhexiang Pills and Argatroban Injection can effectively improve the acute symptoms of ischemic stroke, significantly improve the degree of brain nerve damage, and effectively reduce the inflammatory response.

R971